Navigation Links
Curemark CEO Presents at Epigenomics Conference
Date:8/24/2009

RYE, N.Y., Aug. 24 /PRNewswire/ -- Curemark Founder and CEO Dr. Joan Fallon delivered the Industry Keynote address at the Third International Epigenomics, Sequencing 2009 Conference at Harvard Medical School on July 14th.

Dr. Fallon's selection to address this cutting-edge conclave is particularly significant, since epigenetics is the study of heritable changes in gene function that occur without a change in the DNA sequence. Presenters at the session showcased many leading researchers, representing Harvard, Columbia and Duke Universities along with MIT and many others.

Dr. Fallon's message focused on Curemark's patented new science, which distinguishes a subset of children with autism. Labeled most recently by the geneticists as "the autisms", the multiple phenotypes which fall on the autism spectrum have yet to be fully delineated on a gene level. Curemark's science provides a route to identify a specific, diagnosable subset of children with autism.

"I'm honored to have been selected, among such distinguished leaders in both academia and industry, to speak at this conference," stated Fallon. "The opportunity to discuss Curemark's science in front of this esteemed group is so important to children with autism around the world as well as

to Curemark," she continued.

Curemark is presently conducting a FDA phase III clinical trial for autism.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases especially those with dysautonomic components by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit '/>"/>

SOURCE Curemark LLC
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an online ... million in 12% per annum short term debt financing. ... initial drawdown of $500,000, with accrued interest and principal ... with accrued interest and principal repayable in one year ... cashflow positive for any calendar month prior to December ...
(Date:12/16/2009)... 16 EuroPharma, Inc. signs exclusive ... use of super absorbency BCM-95® curcumin and ... The exclusive distribution territory for these ... store channel and professional channel, which includes ... BCM-95® is a highly absorbable curcumin. ...
(Date:12/16/2009)... 16 RealMed has been ranked ... the 2009 Top 20 Best in ... report. RealMed is a dynamic revenue cycle ... processing between healthcare providers and all ... firm specializing in vendor performance measurement in ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 59658 1MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 59658 2MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 59658 3New FDA Study Seeks Feedback on Lasik Surgery 59656 1New FDA Study Seeks Feedback on Lasik Surgery 59656 2Scientists Provide First Map of Complete Human Epigenome 59653 1Scientists Provide First Map of Complete Human Epigenome 59653 2
... Germany, June 5, 2007 – This,year’s American ... sees a wealth of promising new data ... further demonstrating the consistent efficacy and,versatility of ... of metastatic colorectal cancer (mCRC) and squamous ...
... Second Multinational Phase III Study Provides Further ... Inhibition in the Treatment,of Rheumatoid Arthritis, BASEL, ... (1), the second multinational phase III Actemra,(tocilizumab) ... that a greater proportion of patients treated ...
Other Medicine Technology:Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 2Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 4Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 5Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 6Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 7Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 8New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4
(Date:12/16/2009)... Dec. 16 For wounded U.S. ... Center in Washington, D.C., the holidays can be a ... to travel home rely more than ever on the ... This week, calling home just got easier for Walter ... calling cards, which will provide hundreds of minutes of ...
(Date:12/16/2009)... Scientists pinpoint seven that increase susceptibility to disease ... genes associated with increased susceptibility to leprosy have ... , The researchers, who analyzed more than 10,000 ... in China, said their discovery highlights the important ... the development of leprosy. , "Though leprosy is ...
(Date:12/16/2009)... fatty acids commonly found in fatty fish and ... research published by the American Psychological Association. The ... found in people with schizophrenia; bipolar, obsessive-compulsive, and ... of the nervous system. , The study, ... provides more evidence that fish is brain food. ...
(Date:12/16/2009)... technology and the provider of the optimal paper-based e-data capture ... among the Fastest Growing Technology Companies on the Deloitte Technology ... ... (PRWEB) December 16, 2009 -- Kayentis provides ... of handwritten data. Kayentis targets the Healthcare and Life Sciences ...
(Date:12/16/2009)... all-time low, government report shows, , , WEDNESDAY, Dec. 16 ... States has reached almost 78 years, a record high, ... 2007, women can expect to live to 80.4 years ... the report from the U.S. Centers for Disease Control ... expect to live longer than their parents, life expectancy ...
Breaking Medicine News(10 mins):Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:Leprosy Genes Identified 2Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3
... attacks and related cardiovascular problems occurring in people who ... long sought medications to increase the amount of this ... a new review of 31 randomized controlled trials published ... that so far, only modest evidence supports the use ...
... University Medical Center researchers have demonstrated using functional ... increased in stroke and traumatic brain injury survivors ... treatment that helps these patients recover lost vision. ... peer-reviewed journal Neurorehabilitation and Neural Repair on Aug. ...
... their physician will you be delivering my baby" Dr. ... determine whether obstetric outcomes differed between women whose babies ... by an on-call obstetrician who did not provide antenatal ... single term births between 1991 and 2001 at the ...
... indicates that the loss of two types of brain ... of symptoms associated with Parkinson,s disease. , The evidence, ... loss of both norepinephrine and dopamine neurons and the ... was originally thought that the loss of only dopamine ...
... safe and may produce beneficial changes in the brains ... to an article posted online today that will appear ... Neurology, one of the JAMA/Archives journals. , In patients ... myelin sheaths that protect nerve cells in the brain ...
... spawns an enzyme that inactivates two tumor-suppressing genes, ultimately ... cancer cells, researchers at The University of Texas M. ... of the journal Cell. , "This is a completely ... targets for clinical intervention," senior author Mien-Chie Hung, Ph.D., ...
Other Medicine News:Health News:New review suggests caution on drugs to raise 'good' cholesterol 2Health News:New review suggests caution on drugs to raise 'good' cholesterol 3Health News:Vision restoration therapy shown to improve brain activity in brain injured patients 2Health News:Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinson's symptoms 2Health News:DNA vaccine against multiple sclerosis appears safe, potentially beneficial 2Health News:Pathway links inflammation, angiogenesis and breast cancer 2Health News:Pathway links inflammation, angiogenesis and breast cancer 3
... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...
... Knee design includes several innovative ... porous coating option for stable ... unique bone preserving posterior stabilizing ... to maximize range of motion, ...
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
Scorpio CR Knee is designed to address normal knee kinematics, range of motion (ROM) and polyethylene wear....
Medicine Products: